Most women who stop hormone replacement therapy experience a return of menopausal symptoms, though they’re often milder than the original ones. In a Swedish population study, 87% of women who had hot flashes before starting therapy saw them come back after stopping. Beyond the familiar symptoms, discontinuation triggers measurable changes in cholesterol, bone density, sleep, and mood that are worth understanding before you make the decision.
Hot Flashes and Night Sweats Come Back
Vasomotor symptoms, the hot flashes and night sweats that drove most women to start therapy in the first place, are the most common and noticeable effect of stopping. The return rate is high regardless of how long you’ve been on treatment. Women who used therapy for less than a year, two to four years, or five-plus years all saw similar recurrence rates. The reassuring finding: most women reported that the returning flashes were less frequent and less bothersome than the ones they had before starting therapy. Your body has continued aging through menopause while on treatment, so the hormonal shift at discontinuation is smaller than the one that originally triggered your symptoms.
Vaginal Dryness and Urinary Changes
Estrogen keeps vaginal and urinary tract tissue thick, elastic, and lubricated. When you stop systemic hormone therapy, those tissues lose that support and begin to thin. Unlike hot flashes, which often fade on their own over time, vaginal and urinary symptoms tend to be progressive. They don’t resolve with waiting and typically worsen the longer you go without estrogen. Even 10% to 20% of women still on systemic estrogen have some degree of vaginal dryness, so stopping makes the situation more pronounced. Local estrogen products (vaginal creams, rings, or tablets) can address this without the systemic exposure that comes with pills or patches, which is why many women switch to a local option after discontinuing full HRT.
Bone Density Drops Quickly
Estrogen slows the natural bone breakdown that accelerates after menopause. When you stop, bone loss resumes at a pace that depends partly on how long you were on therapy. Women who used HRT for about a year lost bone at a rate of roughly 0.5% per year at the hip and 0.8% per year at the spine after stopping. Women who had been on it for three years lost bone faster: about 1% per year at both the hip and spine. These losses are steepest in the first two to three years after discontinuation, then tend to slow. If you’re already at risk for osteoporosis, a bone density scan before or shortly after stopping can help you and your provider decide whether you need a different bone-protective treatment.
Cholesterol Shifts Upward
Estrogen has a favorable effect on blood lipids, and removing it reverses that benefit. Women who stopped HRT saw their total cholesterol and LDL (“bad”) cholesterol rise by an average of more than 20 mg/dL compared to women who continued therapy. That’s a meaningful jump. Other cardiovascular markers, including blood pressure, triglycerides, HDL cholesterol, insulin, and glucose, did not change significantly after stopping. The cholesterol increase was successfully offset in studies by intensive lifestyle changes, particularly improvements in diet and exercise. If your cholesterol was borderline before starting HRT, it’s worth getting a lipid panel checked a few months after discontinuation.
Sleep Gets Worse
Sleep disruption is one of the fastest effects to appear. In a randomized trial, women who suspended hormone therapy for just one to two months reported significantly more trouble falling asleep, more nights of poor sleep, and more early waking compared to women who stayed on treatment. After two months off therapy, women reported 46% more days with trouble falling asleep and 46% more days of sleeping poorly. Waking too early increased by 31%. These numbers held even after accounting for the effect of returning hot flashes, suggesting that estrogen withdrawal affects sleep through additional pathways beyond just night sweats.
Mood and Emotional Changes
Observational studies estimate that 5% to 10% of women develop new depressive symptoms after discontinuing hormone therapy. But the risk is not evenly distributed. Women who had depression during perimenopause are far more vulnerable. In a controlled trial, 79% of women with a history of perimenopausal depression developed depressive symptoms when estrogen was withdrawn, compared to just 7% of women without that history. Irritability and anxiety scores roughly tripled in the susceptible group during the withdrawal period. If you went through a difficult emotional transition during perimenopause, this is something to monitor closely and discuss with your provider before stopping.
Breast Cancer Risk Gradually Declines
One of the most common reasons women stop HRT is concern about breast cancer, and the news here is mostly reassuring. For women who used combined estrogen-progestogen therapy for fewer than five years, any excess breast cancer risk disappears within five years of stopping. The picture is more complicated for long-term users (more than five years), and it depends on the type of progestogen used. Women who took estrogen with natural progesterone or dydrogesterone saw their risk return to baseline within a few years of stopping. Women who took estrogen with synthetic progestagens had a modestly elevated risk that persisted for five to ten years after cessation, though the absolute increase remains small. Estrogen-only therapy, used by women who have had a hysterectomy, carries a lower breast cancer risk profile overall.
Tapering vs. Stopping Abruptly
You might assume that gradually reducing your dose would make the transition smoother, and the data partially supports that. Women who tapered reported fewer menopausal symptoms after discontinuation than women who stopped abruptly. However, tapering came with a surprising downside: women who tapered were about twice as likely to restart therapy compared to those who quit cold turkey. The likely explanation is that tapering extends the period of symptom awareness, giving women more time to reconsider. Current guidelines note that tapering and abrupt cessation show no significant difference in ultimate symptom recurrence, so the choice comes down to personal preference.
Other factors mattered more than method. Younger women, those who had milder symptoms before starting therapy, and those who rated their overall health as good or better all had an easier time with discontinuation regardless of how they stopped.
There’s No Required Stopping Point
Updated 2025 guidelines from international menopause societies have moved away from rigid time limits on hormone therapy. There is no universally recommended duration, and routine discontinuation at age 60 or 65 is no longer considered necessary. For healthy women who started HRT before age 60 or within ten years of menopause, and who have low cardiovascular and breast cancer risk, long-term use may be appropriate as long as they use the lowest effective dose and have regular follow-up. For women over 65, periodic attempts to taper or stop are advised, paired with reassessment of overall health. Women who went through early menopause (before age 40) are advised to continue at least until the typical age of natural menopause, around 51, to protect their bones and heart.